Genetics

Research Alliance Expanded on BRCA1 Gene Link to Cancers

Published in Women's Health Weekly, June 24th, 1996

Onyx Pharmaceuticals, Richmond, California, announced an extension and expansion of its research alliance with Eli Lilly and Company, to focus on BRCA1, a tumor suppressor gene that is linked to susceptibility for breast and ovarian cancers.

Eli Lilly continues to retain exclusive rights to the BRCA1 gene, which it licensed from Myriad Genetics, Inc. for use in developing therapeutic products. "... work in our collaboration and in the field by ourselves and others has underscored the potential importance of BRCA1 in breast and ovarian cancer," said Hollings Renton, Onyx. "As a result, we are broadening this collaboration to enhance our understanding of BRCA1-related...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1996-06-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry